公开(公告)号：US11547743B2

公开(公告)日：2023-01-10

申请号：US15305049

申请日：2015-04-24

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Ryo Ohori ,  Kanta Horie

IPC: A61K38/18 ,  A61K47/18 ,  A61K47/26 ,  A61K9/19 ,  A61K38/00 ,  A61K47/02

Abstract: An object of the present invention is to provide a lyophilized formulation having improved storage stability of hepatic growth factor compared to conventional lyophilized formulations. The present invention provides a lyophilized formulation comprising (1) a hepatic growth factor, (2) trehalose and (3) one or more compounds selected from the group consisting of arginine, histidine, lysine, meglumine, glutamic acid, aspartic acid, proline, creatine, creatinine, tris(hydroxymethyl)aminomethane, and pharmaceutically acceptable salts thereof.

公开(公告)号：US11446358B2

公开(公告)日：2022-09-20

申请号：US15305049

申请日：2015-04-24

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Ryo Ohori ,  Kanta Horie

IPC: A61K38/18 ,  A61K47/18 ,  A61K47/26 ,  A61K9/19 ,  A61K38/00 ,  A61K47/02

Abstract: An object of the present invention is to provide a lyophilized formulation having improved storage stability of hepatic growth factor compared to conventional lyophilized formulations.
The present invention provides a lyophilized formulation comprising (1) a hepatic growth factor, (2) trehalose and (3) one or more compounds selected from the group consisting of arginine, histidine, lysine, meglumine, glutamic acid, aspartic acid, proline, creatine, creatinine, tris(hydroxymethyl)aminomethane, and pharmaceutically acceptable salts thereof.

公开(公告)号：US11324805B2

公开(公告)日：2022-05-10

申请号：US15305049

申请日：2015-04-24

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Ryo Ohori ,  Kanta Horie

IPC: A61K38/18 ,  A61K47/18 ,  A61K47/26 ,  A61K9/19 ,  A61K38/00 ,  A61K47/02

Abstract: An object of the present invention is to provide a lyophilized formulation having improved storage stability of hepatic growth factor compared to conventional lyophilized formulations.
The present invention provides a lyophilized formulation comprising (1) a hepatic growth factor, (2) trehalose and (3) one or more compounds selected from the group consisting of arginine, histidine, lysine, meglumine, glutamic acid, aspartic acid, proline, creatine, creatinine, tris(hydroxymethyl)aminomethane, and pharmaceutically acceptable salts thereof.

公开(公告)号：US20220251171A1

公开(公告)日：2022-08-11

申请号：US17617504

申请日：2020-06-25

Applicant: EISAI R&D MANAGEMENT CO., LTD. ,  BioArctic AB

Inventor： Hiroaki Hagiwara ,  Kanta Horie ,  Kunihiko Kanatsu ,  Yasuharu Ishihara ,  Yasuaki Goto ,  Toru Oki ,  Masafumi Tsuboi ,  Charlotte Sahlin ,  Maria Eriksson ,  Christer Möller

IPC: C07K14/775 ,  G01N33/50 ,  G01N33/92 ,  A61P25/28

Abstract: The present invention relates to novel fragments of apolipoprotein E (ApoE). These ApoE fragments have a variety of uses including as components of vaccine compositions, particularly vaccines for the prevention or treatment of neurological disorders such as Alzheimer's disease. The ApoE fragments may also be used in screening methods and methods of detection.

公开(公告)号：US10537612B2

公开(公告)日：2020-01-21

申请号：US15305049

申请日：2015-04-24

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Ryo Ohori ,  Kanta Horie

IPC: A61K38/18 ,  A61K47/18 ,  A61K47/26 ,  A61K9/19 ,  A61K47/02

Abstract: An object of the present invention is to provide a lyophilized formulation having improved storage stability of hepatic growth factor compared to conventional lyophilized formulations.The present invention provides a lyophilized formulation comprising (1) a hepatic growth factor, (2) trehalose and (3) one or more compounds selected from the group consisting of arginine, histidine, lysine, meglumine, glutamic acid, aspartic acid, proline, creatine, creatinine, tris(hydroxymethyl)aminomethane, and pharmaceutically acceptable salts thereof.

公开(公告)号：US20180263998A1

公开(公告)日：2018-09-20

申请号：US15516567

申请日：2015-10-08

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Yasuhiro Zaima ,  Kazuo Kazama ,  Shuntaro Arase ,  Kentaro Nagane ,  Kanta Horie ,  Yosuke Ueki

IPC: A61K31/542

CPC classification number: A61K31/542 ,  A61K9/2018 ,  A61K9/2054 ,  A61P25/28

Abstract: The present invention provides a pharmaceutical composition comprising a compound represented by formula (1): or N-[3-((4aS,5R,7aS)-2-amino-5-methyl-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-carboxamide, or a pharmaceutically acceptable salt of the foregoing, and a salt of a compound having a C12-22 saturated aliphatic hydrocarbon group.

公开(公告)号：US20170189487A1

公开(公告)日：2017-07-06

申请号：US15305049

申请日：2015-04-24

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Ryo Ohori ,  Kanta Horie

IPC: A61K38/18 ,  A61K47/02 ,  A61K47/18 ,  A61K9/19 ,  A61K47/26

Abstract: An object of the present invention is to provide a lyophilized formulation having improved storage stability of hepatic growth factor compared to conventional lyophilized formulations.The present invention provides a lyophilized formulation comprising (1) a hepatic growth factor, (2) trehalose and (3) one or more compounds selected from the group consisting of arginine, histidine, lysine, meglumine, glutamic acid, aspartic acid, proline, creatine, creatinine, tris(hydroxymethyl)aminomethane, and pharmaceutically acceptable salts thereof.

公开(公告)号：US10117876B2

公开(公告)日：2018-11-06

申请号：US15516567

申请日：2015-10-08

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Yasuhiro Zaima ,  Kazuo Kazama ,  Shuntaro Arase ,  Kentaro Nagane ,  Kanta Horie ,  Yosuke Ueki

IPC: A61K31/542 ,  C07D513/04 ,  A61K9/20

CPC classification number: A61K31/542 ,  A61K9/2018 ,  A61K9/2054 ,  A61P25/28

Abstract: The present invention provides a pharmaceutical composition comprising a compound represented by formula (1): or N-[3-((4aS,5R,7aS)-2-amino-5-methyl-4a,5,7,7a-tetrahydro-4H-furo[3,4-d] [1,3]thiazin-7a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-carboxamide, or a pharmaceutically acceptable salt of the foregoing, and a salt of a compound having a C12-22 saturated aliphatic hydrocarbon group.

公开(公告)号：US10076524B1

公开(公告)日：2018-09-18

申请号：US15516567

申请日：2015-10-08

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Yasuhiro Zaima ,  Kazuo Kazama ,  Shuntaro Arase ,  Kentaro Nagane ,  Kanta Horie ,  Yosuke Ueki

IPC: A61K31/542 ,  C07D513/04 ,  A61K9/20

CPC classification number: A61K31/542 ,  A61K9/2018 ,  A61K9/2054 ,  A61P25/28

Abstract: The present invention provides a pharmaceutical composition comprising a compound represented by formula (1): or N-[3-((4aS,5R,7aS)-2-amino-5-methyl-4a,5,7,7a-tetrahydro-4H-furo[3,4-d] [1,3]thiazin-7a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-carboxamide, or a pharmaceutically acceptable salt of the foregoing, and a salt of a compound having a C12-22 saturated aliphatic hydrocarbon group.

公开(公告)号：US20220378706A1

公开(公告)日：2022-12-01

申请号：US17831863

申请日：2022-06-03

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Edgar Schuck ,  Robert Lai ,  Ishani Savant Landry ,  Bhaskar Rege ,  Mai Miyamoto ,  Sadaharu Kotani ,  Kanta Horie

IPC: A61K9/20 ,  A61P25/28 ,  A61K9/16 ,  A61K9/48 ,  A61K31/437

Abstract: The present invention provides a pharmaceutical composition comprising a PDE9 inhibitor. Specifically, the PDE9 inhibitor is (S)-7-(2-methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[4,3-c]quin olin-4(5H)-one or pharmaceutically acceptable salts thereof.